When was Lundbeck founded?

Lundbeck was founded in 1915 and raised its 1st funding round 96 years after it was founded.

Where is Lundbeck located?

Lundbeck is headquartered in Copenhagen, Denmark. It is registered at 9, Ottiliavej, Valby, 2500.

How many employees does Lundbeck have?

As of Sep 30, 2026, the latest employee count at Lundbeck is 6041.

Is Lundbeck a funded company?

Lundbeck is a funded company, having raised an undisclosed amount across 8 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on 2011.

When was the latest funding round of Lundbeck?

Lundbeck's latest funding was a $***** Grant (prize money) round on Mar 01, 2019, with participation from 1 investor.

What is the annual revenue of Lundbeck?

Annual revenue of Lundbeck is more than $1B as on Dec 31, 2024

Where does Lundbeck rank among its competitors?

Lundbeck ranks 50th amongst 2866 active competitors, of which 971 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Lundbeck?

Lundbeck's top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Lundbeck - 2026 Company Profile, Team, Funding, Competitors & Financials

Lundbeck is an acquired company based in Copenhagen (Denmark), founded in 1915 by Hans Lundbeck. It operates as a Developer of drugs for treating CNS disorders. Lundbeck has raised an undisclosed amount in funding. The company has 2866 active competitors, including 971 funded and 713 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.

Company Details

Developer of drugs for treating CNS disorders. The company's lead candidate is "Eptinezumab" a monoclonal immunoglobulin G1 (IgG1) antibody for migraine and cluster headaches. Also, it develops a pipeline for depression, schizophrenia, Alzheimer's disease, Parkinson's disease, and insomnia.

Website: www.lundbeck.com/global
Social
Registered Address: 9, Ottiliavej, Valby, 2500

Key Metrics

Founded Year

1915

Location

Copenhagen, Denmark

Stage

Acquired

Latest Funding Round

Grant (prize money), Mar 01, 2019, $*****

Investors

Impact Fund Denmark & 1 more

Ranked

50^th among 2866 active competitors

Annual Revenue

$1B+ as on Dec 31, 2024

Employee Count

6,041 as on Sep 30, 2026

Investment & Acquisitions

Longboard Pharmaceutical & 14 more

Similar Companies

Jazz Pharmaceuticals & 580 more

Exit Details

Acquired by Flamma Group (Oct 05, 2026)

View Lundbeck's full profile

Lundbeck is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count
LUNDBECK PHARMA A/S CIN: 56750215 , Denmark, Active	Feb 23, 1958	$1B+ (As on Dec 31, 2024)	21 (As on Mar 31, 2024)
LUNDBECK CHINA HOLDING A/S CIN: 33766939 , Denmark, Deadpooled	Jun 23, 2011	-	-
LUNDBECK COGNITIVE THERAPEUTICS A/S CIN: 28674848 , Denmark, Deadpooled	Dec 13, 2006	-	-
LUNDBECK INDIA PRIVATE LIMITED CIN: U24231KA2002PTC029998 , India, Under liquidation	Jan 16, 2002	0 - ₹10 Cr (As on Mar 31, 2023)	2 (As on Dec 31, 2022)

Lundbeck got acquired by Flamma Group on Oct 05, 2026.

Click here to take a look at Lundbeck's acquisition in detail

Lundbeck has raised funding over 8 rounds. Its first funding round was on 2011. Its latest funding round was a Grant (prize money) round on Mar 01, 2019 for $*****. 1 investor participated in its latest round. Lundbeck has 2 institutional investors.

Here is the list of recent funding rounds of Lundbeck:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 01, 2019	2963918	Grant (prize money)	5185564	8587444	9396471	9664890
Jan 01, 2017	3739238	Grant (prize money)	3175395	7903042	9738939	Europa
Dec 01, 2016	9371288	Grant (prize money)	8180026	5937231	6143817	Europa

Access funding benchmarks and valuations. Sign up today!

View details of Lundbeck's funding rounds and investors

The founders of Lundbeck is Hans Lundbeck. Charl Van Zyl is the CEO of Lundbeck.

Here are the details of Lundbeck's key team members:

Hans Lundbeck: Former Founder of Lundbeck.
Contact Info: 1 email address
Charl Van Zyl: CEO of Lundbeck.

Lundbeck's Board of Directors

Lundbeck's board has 3 active members. Soren Klein-Kristensen, Thomas Bo Bjorn Klee and Michala Fischer-Hansen are part of team.

Here is the list of Lundbeck's board of directors:

Name	Type	Representing	Status	Duration
fgtvraj	Team	-	Current	5y 5m
hrtxzae	Team	-	Current	5y 3m
akntyaj	Team	-	Current	9y 2m

View details of Lundbeck's Founder profiles and Board Members

Lundbeck's employee count trend

Lundbeck has 6,041 employees as of Sep 26. Here is Lundbeck's employee count trend over the years:

Uncover Lundbeck's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Lundbeck include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Lundbeck, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
50th	Lundbeck 1915, Copenhagen (Denmark), Acquired	Developer of drugs for treating CNS disorders	-	Impact Fund Denmark, Europa	63/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Lundbeck's competitors? Click here to see the top ones

Lundbeck has made 7 investments in companies including Naurex and Naurex. Lundbeck has also acquired 8 companies including Longboard Pharmaceutical and Alder.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Oct 14, 2024	Acquisition	Longboard Pharmaceutical	2020	San Diego (United States)
Sep 16, 2019	Acquisition	Alder	2004	Delhi (India)
Sep 16, 2019	Acquisition	Alder Biopharmaceuticals	2004	Bothell (United States)